Because I see Azer-Cel will be first to market and can expand to other liquid cancer indicators as well. Also, it will give BP a complete treatment therapy with CD19 for OnCARlytics which is still the IP with the biggest market potential but least developed of the 3 IP right now. BG has mentioned the registrational clinical trial for Azer-Cel will cost $35M, not sure if this is USD or AUD.
IMU Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)